Subsequently, we also revealed that ROS-NF-кB inhibition abrogated DPP-4i-driven BC metastasis, while abrogation of NRF2-HO-1 attenuated DPP-4i-driven ROS-dependent NF-kB activation in BC cells. Here, NFKB1 is linked to breast cancer.